Bukwang Pharmaceutical Co., Ltd. (KRX: 003000)
South Korea
· Delayed Price · Currency is KRW 5,040.00
+10.00 (0.20%)
Oct 14, 2024, 10:59 AM KST
Bukwang Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 116,583 | 125,928 | 190,909 | 182,491 | 169,660 | 168,194 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | -0 | - | Upgrade
|
| Revenue | 116,583 | 125,928 | 190,909 | 182,491 | 169,660 | 168,194 | Upgrade
|
| Revenue Growth (YoY) | -39.21% | -34.04% | 4.61% | 7.56% | 0.87% | -13.40% | Upgrade
|
| Cost of Revenue | 71,325 | 79,012 | 111,763 | 106,942 | 98,319 | 84,842 | Upgrade
|
| Gross Profit | 45,257 | 46,916 | 79,147 | 75,550 | 71,341 | 83,352 | Upgrade
|
| Selling, General & Admin | 47,031 | 51,274 | 49,797 | 43,477 | 45,373 | 53,067 | Upgrade
|
| Research & Development | 33,877 | 34,551 | 24,274 | 22,465 | 18,032 | 17,312 | Upgrade
|
| Other Operating Expenses | 2,768 | 2,078 | 1,345 | 1,317 | 1,563 | 1,242 | Upgrade
|
| Operating Expenses | 80,687 | 84,413 | 79,377 | 69,928 | 67,313 | 73,814 | Upgrade
|
| Operating Income | -35,430 | -37,497 | -230.64 | 5,622 | 4,028 | 9,537 | Upgrade
|
| Interest Expense | -3,808 | -3,808 | -1,760 | -1,408 | -1,515 | -90.85 | Upgrade
|
| Interest & Investment Income | 3,080 | 3,080 | 1,440 | 268.16 | 1,313 | 2,055 | Upgrade
|
| Earnings From Equity Investments | -640.56 | -1,501 | 58.57 | -1,361 | -2,838 | -783.95 | Upgrade
|
| Currency Exchange Gain (Loss) | -177.44 | -177.44 | 88.47 | 322.31 | -2,105 | 76.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,139 | 867.73 | -113.73 | 33.63 | -401.19 | -368.31 | Upgrade
|
| EBT Excluding Unusual Items | -35,837 | -39,036 | -517.65 | 3,477 | -1,518 | 10,425 | Upgrade
|
| Gain (Loss) on Sale of Investments | -564.4 | -564.4 | -567.47 | 90.53 | -3,297 | -11,791 | Upgrade
|
| Gain (Loss) on Sale of Assets | 30.64 | 30.64 | 52.25 | 220.05 | 54.25 | 3.42 | Upgrade
|
| Asset Writedown | - | - | - | - | -3,539 | - | Upgrade
|
| Pretax Income | -36,370 | -39,569 | -1,033 | 3,787 | -8,300 | -1,362 | Upgrade
|
| Income Tax Expense | -2,403 | -5,163 | 3,216 | 6,584 | 1,805 | 6,073 | Upgrade
|
| Earnings From Continuing Operations | -33,967 | -34,407 | -4,249 | -2,797 | -10,105 | -7,435 | Upgrade
|
| Minority Interest in Earnings | 2,415 | 3,077 | 1,774 | 1,880 | 2,902 | 22.48 | Upgrade
|
| Net Income | -31,551 | -31,330 | -2,475 | -916.62 | -7,203 | -7,412 | Upgrade
|
| Net Income to Common | -31,551 | -31,330 | -2,475 | -916.62 | -7,203 | -7,412 | Upgrade
|
| Shares Outstanding (Basic) | 69 | 68 | 68 | 68 | 69 | 72 | Upgrade
|
| Shares Outstanding (Diluted) | 69 | 68 | 68 | 68 | 69 | 72 | Upgrade
|
| Shares Change (YoY) | 0.72% | - | -0.01% | -0.25% | -4.24% | -1.37% | Upgrade
|
| EPS (Basic) | -459.48 | -457.67 | -36.15 | -13.39 | -104.95 | -103.43 | Upgrade
|
| EPS (Diluted) | -459.80 | -458.00 | -36.15 | -13.39 | -105.00 | -103.64 | Upgrade
|
| Free Cash Flow | 20,249 | -12,196 | 12,163 | 25,740 | -1,194 | -26,945 | Upgrade
|
| Free Cash Flow Per Share | 294.88 | -178.17 | 177.68 | 375.98 | -17.40 | -375.98 | Upgrade
|
| Gross Margin | 38.82% | 37.26% | 41.46% | 41.40% | 42.05% | 49.56% | Upgrade
|
| Operating Margin | -30.39% | -29.78% | -0.12% | 3.08% | 2.37% | 5.67% | Upgrade
|
| Profit Margin | -27.06% | -24.88% | -1.30% | -0.50% | -4.25% | -4.41% | Upgrade
|
| Free Cash Flow Margin | 17.37% | -9.69% | 6.37% | 14.10% | -0.70% | -16.02% | Upgrade
|
| EBITDA | -31,319 | -33,204 | 4,886 | 10,465 | 10,186 | 15,377 | Upgrade
|
| EBITDA Margin | -26.86% | -26.37% | 2.56% | 5.73% | 6.00% | 9.14% | Upgrade
|
| D&A For EBITDA | 4,110 | 4,292 | 5,117 | 4,843 | 6,158 | 5,840 | Upgrade
|
| EBIT | -35,430 | -37,497 | -230.64 | 5,622 | 4,028 | 9,537 | Upgrade
|
| EBIT Margin | -30.39% | -29.78% | -0.12% | 3.08% | 2.37% | 5.67% | Upgrade
|
| Effective Tax Rate | - | - | - | 173.85% | - | - | Upgrade
|
| Advertising Expenses | - | 12,764 | 12,181 | 6,622 | 8,784 | 13,021 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.